Nirmal Bang recommends buying Epigral and Suryoday Small Finance Bank for May. Epigral shows growth potential with revenue and PAT increase despite challenges. Suryoday is expected to focus on growth after the restructuring exercise, aiming for advances growth and narrowing the valuation gap.